TrialJournal of diabetes science and technology2012

An adaptive, dose-finding, seamless phase 2/3 study of a long-acting glucagon-like peptide-1 analog (dulaglutide): trial design and baseline characteristics.

Mary Jane Geiger et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.